News | Breast Imaging | February 02, 2021

Volpara Acquires Breast Cancer Risk Assessment Company CRA Health, LLC.

Combination will deliver personalized breast care to more women across all care settings

Volpara Health, a health technology software company whose integrated breast care platform assists in the delivery of personalized patient care, announced the acquisition of CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital.

Getty Images

February 2, 2021 — Volpara Health, a health technology software company whose integrated breast care platform assists in the delivery of personalized patient care, announced the acquisition of CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital.

Volpara is paying $18M to acquire all outstanding equity of CRA, with a further $4M payable upon its meeting key performance targets over the next 18 months.

CRA Health has been singularly focused on cancer risk assessment for more than 15 years and conducts more than 2M assessments annually. CRA software is cloud-based and tightly integrated into EHR systems. CRA receives patient information, including breast density, and returns the risk of breast cancer alongside appropriate recommendations, including whether additional imaging or genetics testing is needed according to established guidelines. Importantly, CRA has electronic interfaces established with all the major genetics companies.

CRA Health and Volpara Health – both born out of scientific research at Harvard Medical School and Oxford University – have long shared the common mission of saving more families from cancer and have collaborated on major projects like the on-going UK PROCAS project for personalized breast care.

For more than a decade, Volpara Science, a set of clinically validated algorithms that use AI to assess breast tissue composition and imaging quality, has helped more than 27 percent of all breast centers in the US optimize mammography workflow and deliver personalized care.

Combining the two companies will allow us to identify and deliver personalized breast care to more high-risk women across all care settings:  obgyns, primary care providers, oncology specialists, and breast centers. 

Ralph Highnam, Ph.D., Group CEO of Volpara, said: "The acquisition of CRA is very significant for Volpara. CRA is a leading provider of risk assessment tools within major EHR systems and has integrations already established with the main genetics companies. CRA brings world-class knowledge about risk and genetics. CRA will accelerate us on our mission to save families from cancer by preventing advanced stage breast cancer."

Women in the US are increasingly being recommended for risk assessments, including genetic testing in some cases, to supplement traditional mammography screening. Most notably:

  • The US Centers for Disease Control (CDC) is promoting risk and genetics testing and has recently launched a new marketing campaign.
  • The American College of Radiology and other groups are recommending risk assessment at age 30 to set down screening protocols.
  • Many insurers are now reimbursing for MRI and genetics testing for high-risk women.
  • The US government as part of its value-based care initiative — Merit-based Incentive Payment System — has included conducting breast cancer risk assessment as a key quality metric that can contribute to a positive adjustment to annual Medicare reimbursement.

Both CRA and Volpara have experienced strong growth despite the pandemic, signaling the value placed on using evidence to medically necessitate genetic testing and additional imaging. Volpara Health recently reported its largest-ever Q3 sales performance with an Annual Recurring Revenue (ARR) of $13.5M — up 20% compared to the previous corresponding period — driven by increasing demand for the Volpara Breast Health Platform.

Chester Black, outgoing Chair of CRA, said: "With the tailwinds behind cancer risk assessment and ensuring all women get the right screening at the right time building globally, we are delighted to join Volpara, a company that is substantially larger and enjoys the most scientifically-validated technology platform in the breast screening industry. This is the time to make the most of an opportunity to save many families from cancer in the United States and beyond."

For more information: www.volparahealth.com 

Related Content

News | Breast Imaging | September 20, 2021
September 20, 2021 — ImageCare Centers is unveiling its new “PINK Better Mammo” service with the addition of...
Shimadzu Medical Systems USA, a leading manufacturer of advanced medical X-ray imaging systems, has announced that the Trinias unity edition product line has been awarded a contract from Vizient, Inc., a healthcare performance improvement company, effective Sept. 1, 2021.
News | X-Ray | September 17, 2021
September 17, 2021 — Shimadzu Medical Systems USA, a leading manufacturer of advanced medical...
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
This is an example of 3-D ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

This is an example of TriVu ultrasound imaging on a breast, designed to help increase efficiency and diagnostic accuracy in any practice. Image courtesy of Hologic.

Feature | Breast Imaging | September 15, 2021 | By Jennifer Meade
The...
While the Mammography Quality Standards Act (MQSA) and the introduction of EQUIP (Enhancing Quality Using the Inspection Program) have been successful in standardizing and enhancing mammographic imaging quality, inadequate breast positioning can dramatically impact the ability of radiologists and technicians to quickly and accurately detect breast cancer and potentially malignant lesions in their patients

Getty Images

Feature | Mammography | September 15, 2021 | By Christopher Austin, M.D. and Randy D. Hicks, M.D., MBA
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
Feature | Information Technology | September 15, 2021 | By Kumar Goswami
Healthcare organizations today are storing petabytes of medical imaging data — lab slides,...
Revenues for teleradiology reading service providers are forecast to follow a similar profile over this period.

Outlook for 2021 and Beyond. As displayed in the figure below, these six market drivers are projected to result in teleradiology reading service volumes increasing by 21% in 2021 and nearly doubling by 2025. Revenues for teleradiology reading service providers are forecast to follow a similar profile over this period.

Feature | Teleradiology | September 15, 2021 | By Arun Gill
The closely tied relationship between...